Stock Track | Novavax Soars 5.05% on Monday Amid Analyst Buy Ratings and Positive Outlook

Stock Track

2024-11-18

Novavax (NVAX) stock surged 5.05% on Monday's intraday trading session, boosted by bullish analyst ratings and recommendations highlighting the company's strategic transformation and growth prospects.

B. Riley analyst Mayank Mamtani maintained a "Buy" rating on Novavax, adjusting the price target from $26 to $22. Mamtani's analysis cited the company's strategic refocusing efforts and potential for growth opportunities in the global vaccine market.

Other analysts polled by Capital IQ also expressed an overall positive outlook on Novavax, with average ratings of "Outperform" and price targets ranging from $9 to $25. The favorable analyst sentiment appears to be driving investor interest and contributing to the stock's upward momentum.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1119169415"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119169415\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1119169415?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119169415","market":"hk","top_or_hot":-1,"title":"Stock Track | Novavax Soars 5.05% on Monday Amid Analyst Buy Ratings and Positive Outlook","media":"Stock Track","content":"<html><body><p>Novavax (NVAX) stock surged 5.05% on Monday's intraday trading session, boosted by bullish analyst ratings and recommendations highlighting the company's strategic transformation and growth prospects.</p>\n<p>B. Riley analyst Mayank Mamtani maintained a \"Buy\" rating on Novavax, adjusting the price target from $26 to $22. Mamtani's analysis cited the company's strategic refocusing efforts and potential for growth opportunities in the global vaccine market.</p>\n<p>Other analysts polled by Capital IQ also expressed an overall positive outlook on Novavax, with average ratings of \"Outperform\" and price targets ranging from $9 to $25. The favorable analyst sentiment appears to be driving investor interest and contributing to the stock's upward momentum.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Novavax Soars 5.05% on Monday Amid Analyst Buy Ratings and Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Soars 5.05% on Monday Amid Analyst Buy Ratings and Positive Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-18 23:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax (NVAX) stock surged 5.05% on Monday's intraday trading session, boosted by bullish analyst ratings and recommendations highlighting the company's strategic transformation and growth prospects.</p>\n<p>B. Riley analyst Mayank Mamtani maintained a \"Buy\" rating on Novavax, adjusting the price target from $26 to $22. Mamtani's analysis cited the company's strategic refocusing efforts and potential for growth opportunities in the global vaccine market.</p>\n<p>Other analysts polled by Capital IQ also expressed an overall positive outlook on Novavax, with average ratings of \"Outperform\" and price targets ranging from $9 to $25. The favorable analyst sentiment appears to be driving investor interest and contributing to the stock's upward momentum.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"諾瓦瓦克斯醫藥","start_time":0,"source_url":"","article_id":"1119169415","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119169415","pubTimestamp":1731942403,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novavax  stock surged 5.05% on Monday's intraday trading session, boosted by bullish analyst ratings and recommendations highlighting the company's strategic transformation and growth prospects.B. Riley analyst Mayank Mamtani maintained a \"Buy\" rating on Novavax, adjusting the price target from $26 to $22. Mamtani's analysis cited the company's strategic refocusing efforts and potential for growth opportunities in the global vaccine market.Other analysts polled by Capital IQ also expressed an ov","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"由于分析师给予买入评级和积极前景，Novavax股票周一飙升5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax (NVAX) stock surged 5.05% on Monday's intraday trading session, boosted by bullish analyst ratings and recommendations highlighting the company's strategic transformation and growth prospects.\nB. Riley analyst Mayank Mamtani maintained a \"Buy\" rating on Novavax, adjusting the price target from $26 to $22. Mamtani's analysis cited the company's strategic refocusing efforts and potential for growth opportunities in the global vaccine market.\nOther analysts polled by Capital IQ also expressed an overall positive outlook on Novavax, with average ratings of \"Outperform\" and price targets ranging from $9 to $25. The favorable analyst sentiment appears to be driving investor interest and contributing to the stock's upward momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}